Although RA is associated with significant morbidity, the increasing number of effective drugs and modes of action has improved the disease outcome. Currently, several US Food and Drug Administration ...

IL-17 is a proinflammatory cytokine mediating protumorigenic and proangiogenic effects. Monoclonal antibodies targeting IL-17/IL-17-receptor or impairing expansion of IL-17-producing cells may ...

Emerging evidence supports the argument that psoriatic arthritis arises from two pathways and that affected immune cells may ...

We report here the expression of functional IL-2 receptor (IL-2R) on mature splenic dendritic cells (DC) and synergistic effect of IL-2 on IFN-gamma production by DC. IL-2 augmented IL-12-dependent ...

Dr. Yeilding received options to purchase 38,520 shares and restricted stock units (RSUs) to acquire 31,779 shares of Protagonist Therapeutics common stock. The exercise price of the options is $38.98 ...

By binding its cognate receptors (IL-23R/IL-12Rβ1), it stabilises RAR-related-orphan-receptor-gamma-t (RORγt) in T-helper-17 cells, which, in turn, release their effector cytokines IL-17, IL-21 and IL ...

The results of two new studies suggest mutations in the gene encoding the interleukin (IL)-1 receptor antagonist (IL-1Ra) are responsible for a spectrum of childhood inflammatory disorders ...

Among the cytokines produced by T cells, interleukin (IL)-17A (previously known as IL-17) and IL-17F constitute the signature cytokines of the newly ... They enhance their response by stabilising mRNA ...

Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, so is celebrating new late-stage data showing superiority to the class leader.

UCB has been bringing up the rear in the IL-17 inhibitor category with bimekizumab, but now has EU approval for the drug and thinks it can mount a stiff challenge to the leaders, including ...

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR ) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR ), today announced significant progress in ...